Official Title
Impact of Obstructive Sleep Apnea on Covid-19 Outcomes (OSACOVID-19 Study): A Prospective Observational Cohort Study
Brief Summary

Covid-19 infection is an on-going pandemic with worse diagnosis in adults with comorbid conditions such as hypertension and cardiopulmonary diseases. Obstructive sleep apnea (OSA) is common in those comorbidities and may contribute to worse prognosis for the Covid-19 cases.

Detailed Description

The investigators' primary aim is to address the association between the high probability of
having OSA and Covid-19 outcomes within 28 days of the hospitalization.

Secondary outcomes will be conducting a polysomnography in cases with high probability of
having OSA compared to those with low probability, approx. 4 months after the Covid-19
diagnosis, and re-evaluate the association of the verified OSA diagnosis and severity with
the outcomes in the first 4 weeks as well as with the outcomes after 4 months.

Unknown status
COVID
Obstructive Sleep Apnea
Pneumonia

Diagnostic Test: Home Sleep Apnea Testing or In-hospital Polysomnography

Home Sleep Apnea Testing or In-hospital Polysomnography will be conducted 4 to 6 months after the Covid-19 diagnosis

Eligibility Criteria

Inclusion Criteria:

- Adult patients with Covid 19 diagnosis

- Ability to read and speak

- Signed informed consent.

Exclusion Criteria:

- Subjects with limited life expectancy due to advanced renal disease or uncontrolled
malignancies

- Subjects with alcohol dependency

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Turkey
Locations

Marmara University Hospital
Istanbul, Basibuyuk, Turkey

Koc University
Istanbul, Turkey

Koc Healthcare Istanbul American Hospital
İstanbul, Turkey

Yuksel Peker, MD, PhD, Study Chair
Koc University School of Medicine

Koc Healthcare Istanbul American Hospital, Marmara University Hospital
NCT Number
Keywords
Covid
Obstructive Sleep Apnea
Pneumonia
MeSH Terms
Pneumonia
Apnea
Sleep Apnea Syndromes
Sleep Apnea, Obstructive